Pazopanib (CAS 444731-52-6) Anticancer API

Pazopanib (CAS 444731-52-6) is a potent anticancer API classified as a multi-targeted tyrosine kinase inhibitor (TKI). Produced under strict GMP guidelines, it boasts high purity (≥99%) and exceptional molecular stability, ensuring reliable bioactivity in oncology drug formulations. Its unique mechanism targets key signaling pathways involved in tumor angiogenesis and cell proliferation, effectively suppressing tumor growth and metastasis.

This pharmaceutical-grade API adheres to global pharmacopoeia standards (USP/EP/BP), making it ideal for pharmaceutical manufacturers, biotech firms, and cancer research institutions. It offers consistent batch performance, excellent formulation compatibility, and clinically validated efficacy. For those seeking a high-quality, multi-targeted raw material to develop innovative anticancer therapies, Pazopanib stands out as a cost-effective and trusted solution to advance oncology treatment development.